UA50497U - Способ лечения гриппозной инфекции - Google Patents
Способ лечения гриппозной инфекции Download PDFInfo
- Publication number
- UA50497U UA50497U UAU200913348U UAU200913348U UA50497U UA 50497 U UA50497 U UA 50497U UA U200913348 U UAU200913348 U UA U200913348U UA U200913348 U UAU200913348 U UA U200913348U UA 50497 U UA50497 U UA 50497U
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- infection
- influenza
- oseltamivir
- acid
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract description 8
- 238000000034 method Methods 0.000 title abstract description 8
- 206010022000 influenza Diseases 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 15
- 206010062106 Respiratory tract infection viral Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 14
- 229960002684 aminocaproic acid Drugs 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 229960003752 oseltamivir Drugs 0.000 description 13
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- ILSOAHPXYZRFBA-UHFFFAOYSA-N n-benzyl-1-methylpyridin-1-ium-4-carboxamide;iodide Chemical compound [I-].C1=C[N+](C)=CC=C1C(=O)NCC1=CC=CC=C1 ILSOAHPXYZRFBA-UHFFFAOYSA-N 0.000 description 8
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 7
- 238000010171 animal model Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- JNNGEAWILNVFFD-DXNVVGTLSA-N 7-Epiloganic acid Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)C[C@@H](O)[C@@H]2C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JNNGEAWILNVFFD-DXNVVGTLSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000755093 Gaidropsarus vulgaris Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WMQIBEYREGDWOS-UOUCRYGSSA-N Loganic acid Natural products CC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3C[C@H](O)[C@H](C)[C@@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O WMQIBEYREGDWOS-UOUCRYGSSA-N 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- JNNGEAWILNVFFD-UHFFFAOYSA-N epiloganic acid Natural products CC1C(O)CC(C(=CO2)C(O)=O)C1C2OC1OC(CO)C(O)C(O)C1O JNNGEAWILNVFFD-UHFFFAOYSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004349 nearwork-induced transient myopia Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ лечения гриппозной инфекции относится к области медицины, в частности к способам лечения гриппа и острых респираторных вирусных инфекций.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200913348U UA50497U (ru) | 2009-12-22 | 2009-12-22 | Способ лечения гриппозной инфекции |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200913348U UA50497U (ru) | 2009-12-22 | 2009-12-22 | Способ лечения гриппозной инфекции |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA50497U true UA50497U (ru) | 2010-06-10 |
Family
ID=50688611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU200913348U UA50497U (ru) | 2009-12-22 | 2009-12-22 | Способ лечения гриппозной инфекции |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA50497U (ru) |
-
2009
- 2009-12-22 UA UAU200913348U patent/UA50497U/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5647518B2 (ja) | 硫酸化多糖を含有する抗ウイルス性組成物 | |
| US11072648B2 (en) | Mast cell stabilizers for treatment of fever | |
| CN101437504A (zh) | 含金属的杀病毒组合物及其用途 | |
| Oxford et al. | Targeting influenza virus neuraminidase—a new strategy for antiviral therapy | |
| TWI453026B (zh) | 魚針草萃取物及其純化物抗流感病毒之用途 | |
| WO2017201030A1 (en) | Methods of treating viral infection | |
| Longley et al. | Effect of isoprinosine against challenge with A (H3N2)/Hong Kong influenza virus in volunteers | |
| EP3934653B1 (en) | Azelastine as antiviral treatment | |
| UA50497U (ru) | Способ лечения гриппозной инфекции | |
| Hayden et al. | Comparative therapeutic effect of aerosolized and oral rimantadine HC1 in experimental human influenza A virus infection | |
| US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
| RU2395295C2 (ru) | Способ профилактики заболевания, вызванного вирусом гриппа птиц а/н5n1 | |
| RU2523554C1 (ru) | Способ защиты организма от инфекции, вызванной штаммами субтипа h1n1 вируса гриппа а препаратом на основе альфа-2 интерферона человека | |
| Lokwani et al. | Swine flu: an overview | |
| RU2502512C2 (ru) | Способ лечения гриппа птиц | |
| Zhou et al. | Experimental study on pharmacodynamics of pudilan xiaoyan oral liquid for preventing and treating respiratory virus infection | |
| Zheng et al. | In vitro and in vivo antiviral effect of Fufang Yinhua Jiedu granules (FFYH) combined with oseltamivir against influenza A virus | |
| Prusty et al. | COVID-19 Pandemic: Epidemiology, diagnosis, and treatment knowledge | |
| Manjuladevi et al. | Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research | |
| Mandal et al. | PROTECTIVE EFFECT OF CURCUMA LONGA (TURMERIC) AND ITS ACTIVE INGREDIENT CURCUMIN AGAINST COVID-19: A MINI REVIEW | |
| CN111166762A (zh) | 辅酶a在制备治疗或预防禽流感病毒感染的药物中的应用 | |
| Sharti et al. | Immunomodulatory Effects of Statins in the Treatment and Prophylaxis of Influenza Viruses | |
| CN113667711A (zh) | 一种基于自噬-外泌通路调节巨噬细胞极化的方法及其用途 | |
| CN110559291A (zh) | 联苯苄唑在制备治疗或预防流感病毒感染的药物中的应用 | |
| Couch | Influenza: Advances in Knowledge of Impact and Approaches to Control |